isoniazid has been researched along with zithromax in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Barbachyn, MR; Brickner, SJ; Cynamon, MH; Ford, CW; Glickman, SE; Grega, KC; Hendges, SK; Hutchinson, DK; Kilburn, JO; Klemens, SP; Toops, DS; Zurenko, GE | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Connell, TG; Curtis, N; Ritz, N; Robins-Browne, R; Sievers, A; Tebruegge, M | 1 |
| Gaillard, JL; Jackson, M; McDonnell, G; Niederweis, M; Skovierová, H; Svetlíková, Z | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arora, K; Barry, C; Boshoff, HI; Deschamps, J; Green, JM; Konaklieva, MI; Kuskovsky, R; Lloyd, D; Plotkin, BJ | 1 |
| Abughali, N; Auletta, J; Esper, F; LaBeaud, AD; Lancioni, C | 1 |
| Elkington, PT; Friedland, JS; Gardiner, H; Kubler, A; Prasad, R; Singh, A; Singh, S; Singh, UK | 1 |
| Patsche, CB; Svensson, E; Wejse, C | 1 |
| Calender, A; Israel-Biet, D; Pacheco, Y; Valeyre, D | 1 |
2 review(s) available for isoniazid and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Autophagy; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Host-Pathogen Interactions; Humans; Isoniazid; Lung; Pandemics; Pneumonia, Viral; Pulmonary Edema; Rifampin; Sarcoidosis; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severity of Illness Index | 2020 |
15 other study(ies) available for isoniazid and zithromax
| Article | Year |
|---|---|
Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microbial Sensitivity Tests; Mycobacterium avium; Mycobacterium tuberculosis; Oxazoles; Rats | 1996 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics.
Topics: Antitubercular Agents; BCG Vaccine; Microbial Sensitivity Tests; Mycobacterium bovis | 2009 |
Role of porins in the susceptibility of Mycobacterium smegmatis and Mycobacterium chelonae to aldehyde-based disinfectants and drugs.
Topics: Antitubercular Agents; Disinfectants; Drug Resistance, Bacterial; Glutaral; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Mycobacterium chelonae; Mycobacterium smegmatis; o-Phthalaldehyde; Porins | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
C4-Phenylthio β-lactams: Effect of the chirality of the β-lactam ring on antimicrobial activity.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Macrophages; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Moraxella catarrhalis; Mycobacterium tuberculosis; Structure-Activity Relationship; Sulfhydryl Compounds | 2019 |
Pulmonary tuberculosis presenting as fever without source in a pediatric patient with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Azithromycin; Child, Preschool; Combined Modality Therapy; Contact Tracing; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Ethambutol; Fever of Unknown Origin; Humans; Immunocompromised Host; Isoniazid; Lymphopenia; Male; Mycobacterium tuberculosis; Pneumonectomy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Vincristine | 2009 |
Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.
Topics: Antitubercular Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Epithelial Cells; Fibroblasts; Fluoroquinolones; Humans; Isoenzymes; Isoniazid; Lung; Matrix Metalloproteinases; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Primary Cell Culture; Rifampin; Stromal Cells; Tuberculosis, Pulmonary | 2014 |
Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Lung; Lung Diseases; Mycobacterium; Mycobacterium Infections; Pyrazinamide; Radiography | 2014 |